

Sodium thiosulfate (Pedmark®)

Place of Service

Office Administration
Outpatient Facility Administration
Infusion Center Administration
Home Infusion Administration

HCPs: J0208 per 100 mg

Condition(s) listed in policy (see criteria for details)

- [Reduction of risk for cisplatin-associated ototoxicity](#)

AHFS therapeutic class: antidote

Mechanism of action: cisplatin neutralizer

(1) Special Instructions and Pertinent Information

Covered under the medical benefit, please submit clinical information for prior authorization review.

(2) Prior Authorization/Medical Review is required for the following condition(s)

All requests for sodium thiosulfate (Pedmark®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Reduction of risk for cisplatin-associated ototoxicity

1. Pediatric patient is receiving a cisplatin-based regimen for a localized, non-metastatic solid tumor

Covered Dose:

Actual Body Weight	Covered dose	Frequency
Less than 5 kg	Up to 10 g/m ² IV	Administered 6 hours after completion of each cisplatin infusion and at least 10 hours before the next cisplatin infusion
5 to 10 kg	Up to 15 g/m ² IV	
Greater than 10 kg	Up to 20 g/m ² IV	

Coverage period

Length of cisplatin chemotherapy regimen

ICD-10:

T45.1X5A-T45.1X5S

(3) The following condition(s) DO NOT require Prior Authorization/Preservice

All requests for sodium thiosulfate (Pedmark®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

(4) This Medication is NOT medically necessary for the following condition(s):

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

(5) Additional Information

How supplied:

- 12.5 grams/100 mL (125 mg/mL) single-dose vial

Commercial

Sodium thiosulfate (Pedmark®)

(6) References

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- Pedmark® (sodium thiosulfate) [Prescribing information]. Hoboken, NJ: Fennec Pharmaceuticals, Inc.; 2022.

(7) Policy Update

Date of last review: 4Q2023

Date of next review: 4Q2024

Changes from previous policy version:

- No clinical change to policy following routine annual review.

*BSC Drug Coverage Criteria to Determine Medical Necessity
Reviewed by P&T Committee*